The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
12-Mar-09
$46.9 billion
Target:
Genentech, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company
18-Feb-14
$25.1 billion
Target:
Forest Laboratories Inc.
Acquiror:
Actavis plc
Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.
24-Mar-06
$21.2 billion
Target:
Schering AG
Acquiror:
Bayer AG
Advised Bayer on its public offer for Schering, an international pharmaceuticals group based in Berlin, Germany
27-Mar-18
$13.0 billion
Target:
Novartis AG’s 36.5% stake in Consumer Health Joint Venture
Acquiror:
GlaxoSmithKline plc
Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture
15-Dec-10
$12.9 billion
Target:
Alcon, Inc.
Acquiror:
Novartis AG
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
20-May-13
$8.5 billion
Target:
Warner Chilcott, plc
Acquiror:
Actavis, Inc.
Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc
07-May-18
$7.1 billion
Target:
Frutarom
Acquiror:
International Flavors and Fragrances
Advised IFF, a leading innovator of specialty ingredients, on its acquisition of Frutarom, creating a global leader in Taste, Scent and Nutrition
01-Aug-12
$4.0 billion
Target:
Mediclinic International Limited
Advised Mediclinic International, South Africa’s second largest and Switzerland’s largest provider of private hospital services, on the restructuring of its entire balance sheet, including $2.2 billion debt refinancing in Switzerland and a $0.6 billion rights issue in South Africa
22-Jan-08
$3.4 billion
Target:
Ventana Medical Systems, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a US based provider of histopathology diagnostic equipment
31-Oct-17
$2.0 billion
Target:
Hirslanden Private Hospital Group
Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt
27-Mar-18
$1.6 billion
Target:
Yakult
Acquiror:
Danone
Advised Danone, a leading global food & beverage company, on renewing its strategic partnership with Yakult, a global leader in probiotic beverages, as well as the sale of part of its stake in Yakult
05-Aug-14
$1.3 billion
Target:
Siemens Health Services
Acquiror:
Cerner Corporation
Advised Cerner Corporation, a leader in healthcare information services, on the acquisition of the assets of Siemens Aktiengesellschaft’s healthcare information technology business unit, Siemens Health Services, for $1.3 billion in cash.
04-Dec-13
$850 million
Target:
Megapolis Distribution
Acquiror:
Japan Tobacco Inc
Advised Japan Tobacco Inc in connection with the acquisition of a minority stake in Megapolis Distribution B.V., Russia’s leading tobacco distributor
11-Jun-20
$760 million
Target:
CSM Bakery Solutions
Acquiror:
Rhône Group
Advised the Ad-Hoc Group of First Lien and Second Lien Lenders on consensual out-of-court amend & extend
06-Jul-12
$730 million
Target:
WMF Württembergische Metallwarenfabrik AG
Acquiror:
Kohlberg Kravis Roberts & Co. L.P.
Provided fairness opinion to the Executive Management Board of WMF in connection with the voluntary public takeover offer by Finedining Capital GmbH, a holding company in the possession of funds managed by Kohlberg Kravis Roberts & Co. L.P.
14-Jul-23
$674 million
Target:
Juice Plus+
Advised Juice Plus+, a global health and wellness company in the direct selling space on a comprehensive recapitalization transaction
26-Jun-24
Pending
$630 million
Target:
Haleon plc’s Nicotine Replacement Therapy Business (ex-US)
Acquiror:
Dr. Reddy’s Laboratories
Advising Haleon plc on the sale of its global nicotine replacement therapy business (ex-US) to Dr. Reddy’s Laboratories
16-Jan-12
$428 million
Target:
Robert Wiseman Dairies PLC
Acquiror:
Unternehmensgruppe Theo Müller
Advised Robert Wiseman Dairies PLC, the UK’s largest processor of fresh milk, on a recommended offer from Unternehmensgruppe Theo Müller S.e.c.s.
09-Nov-09
$327 million
Target:
Enzon Pharmaceuticals, Inc.
Acquiror:
Sigma-Tau Pharmaceuticals
Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company
14-Nov-24
$263 million
Target:
Robertet SA
Acquiror:
Fonds Stratégique de Participations and Peugeot Invest SA
Advising Fonds Stratégique de Participations and Peugeot Invest SA, on the acquisition of a 14% stake for €250 million in Robertet SA, world leader in natural products, from DSM-Firmenich AG
06-Dec-18
$165 million
Target:
Storz & Bickel GmbH, related entities and IP
Acquiror:
Canopy Growth Corporation
Advised Canopy Growth, a leading diversified cannabis company, on its acquisition of Storz & Bickel, a premium manufacturer of vaporization devices
17-Dec-15
$130 million
Target:
Airopack Technology Group AG
Acquiror:
Apollo Global Management, LLC
Advised Airopack Technology Group, developer of a revolutionary all-plastic dispenser, on a €120 million debt and equity investment from funds managed by affiliates of Apollo Global Management, and the concurrently announced proposed acquisition of the 50% stake it does not already own in Airolux AG, its joint venture with Resilux NV
26-Apr-23
Pending
$127 million
Target:
Marley Spoon business combination with 468 SPAC II
Acquiror:
468 SPAC II SE
Advising Marley Spoon SE, an ASX listed global subscription-based meal kit provider, on its business combination agreement with 468 SPAC II, simultaneous capital raising and amendment to existing debt facilities
28-Mar-22
Pending
$105 million
Target:
Acacia Pharma Group plc
Acquiror:
Eagle Pharmaceuticals, Inc.
Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise
19-Feb-21
$33 million
Target:
Acacia Pharma Group plc
Acquiror:
N/A
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share